KapellenTM, HeidtmannB, LilienthalE, Rami-MertharB, Engler-SchmidtC, HollRW; DPV-Science-Initiative, the German Working Group for Pediatric Pump Treatment, and the German Competence Network Diabetes: Continuous subcutaneous insulin infusion in neonates and infants below 1 year: Analysis of initial bolus and basal rate based on the experiences from the German Working Group for Pediatric Pump Treatment. Diabetes Technol Ther, 2015; 17:872–879.
2.
FoxLA, BucklohLM, SmithSD, WysockiT, MaurasN: A randomized controlled trial of insulin pump therapy in young children with type 1 diabetes. Diabetes Care, 2005; 28:1277–1281.
3.
LittonJ, RiceA, FriedmanN, OdenJ, LeeMM, FreemarkM: Insulin pump therapy in toddlers and preschool children with type 1 diabetes mellitus. J Pediatr, 2002; 141:490–495.
4.
Mack-FoggJE, OrlowskiCC, JospeN: Continuous subcutaneous insulin infusion in toddlers and children with type 1 diabetes mellitus is safe and effective. Pediatr Diabetes, 2005; 6:17–21.
5.
BlackmanSM, RaghinaruD, AdiS, SimmonsJH, Ebner-LyonL, ChaseHP, TamborlaneWV, SchatzDA, BlockJM, LittonJC, RamanV, FosterNC, KollmanCR, DuBoseSN, MillerKM, BeckRW, DiMeglioLA: Insulin pump use in young children in the T1D Exchange clinic registry is associated with lower hemoglobin A1c levels than injection therapy. Pediatr Diabetes, 2014; 15:564–572.
6.
MianowskaB, FendlerW, TomasikB, MłynarskiW, SzadkowskaA: Effect of insulin dilution on lowering glycemic variability in pump-treated young children with inadequately controlled type 1 diabetes. Diabetes Technol Ther, 2015; 17:605–610.
7.
FrohnertBI, AlonsoGT: Challenges in delivering smaller doses of insulin. Diabetes Technol Ther, 2015; 17:597–599.
AlemzadehR, HoffmannRG, DasguptaM, PartonE: Development of optimal kids insulin dosing system formulas for young children with type 1 diabetes mellitus. Diabetes Technol Ther, 2012; 14:418–422.
10.
Grulich-HennJ, WagnerV, ThonA, SchoberE, MargW, KapellenTM, HaberlandH, RaileK, EllardS, FlanaganSE, HattersleyAT, HollRW: Entities and frequency of neonatal diabetes: data from the diabetes documentation and quality management system (DPV). Diabet Med, 2010; 27:709–712.
11.
BeltrandJ, ElieC, BusiahK, FournierE, BoddaertN, Bahi-BuissonN, VeraM, Bui-QuocE, Ingster-MoatiI, BerdugoM, SimonA, GozaloC, DjeradaZ, FlechtnerI, TreluyerJM, ScharfmannR, CavéH, Vaivre-DouretL, PolakM; Glidkir Study Group. Sulfonylurea therapy benefits neurological and psychomotor functions in patients with neonatal diabetes owing to potassium channel mutations. Diabetes Care, 2015; 38:2033–2041.
12.
De FrancoE, FlanaganSE, HoughtonJA, Lango AllenH, MackayDJ, TempleIK, EllardS, HattersleyAT: The effect of early, comprehensive genomic testing on clinical care in neonatal diabetes: an international cohort study. Lancet, 2015; 386:957–963.
13.
ThurberBW, CarmodyD, TadieEC, PastoreAN, DickensJT, WroblewskiKE, NaylorRN, PhilipsonLH, GreeleySA; United States Neonatal Diabetes Working Group: Age at the time of sulfonylurea initiation influences treatment outcomes in KCNJ11-related neonatal diabetes. Diabetologia, 2015; 58:1430–1435.
14.
MarshallBA, GreenRP, WambachJ, WhiteNH, RemediMS, NicholsCG: Remission of severe neonatal diabetes with very early sulfonylurea treatment. Diabetes Care, 2015; 38:e38–e39.
